Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Immunol. 2012 Apr 23;188(11):5276–5282. doi: 10.4049/jimmunol.1101211

Figure 4. VDRE1, 2 and 3 in the CNS region +1714 to +2554 of the FOXP3 gene are required for enhancing the FOXP3 promoter activity in the presence of 1,25(OH)2VD3.

Figure 4

Human primary CD25−CD4+ T cells were incubated for 5 days with anti-CD3/CD28 Abs and IL- 2 (25 ng/ml) in the presence of 1,25(OH)2VD3 (Vit D, 10 nM) and transfected with a pGL3 basic vector (PGL3), a vector with an insert containing the FOXP3 promoter (FP), or a vector containing the FOXP3 promoter and the CNS region +1714 – +2554 (FP+CNS) with intact or mutated VDRE1, 2 and/or 3 (VDRE1m, 2m, 3m). Cells were incubated for an additional 2 days in the presence of the same stimulation. Luciferase activity was measured and normalized against Renilla activity. Data represent the mean + SEM from 7 independent experiments.